Triple Negative Breast Cancer clinical trials

Explore recruiting triple negative breast cancer clinical trials.

Recruiting triple negative breast cancer studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Triple Negative Breast Cancer trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Randomized, Double-Blind, Phase III Clinical Trial of Neoadjuvant Chemotherapy with Atezolizumab or Placebo in Patients with Triple-Negative Breast Cancer Followed by Adjuvant Continuation of Atezolizumab or Placebo "GeparDouze"

Germany, Spain

Therapeutic confirmatory (Phase III) EU CTIS Study details

A–BRAVE-Trial. ADJUVANT TREATMENT FOR HIGH-RISK TRIPLE NEGATIVE BREAST CANCER PATIENTS WITH THE ANTI-PD-L1 ANTIBODY AVELUMAB: A PHASE III RANDOMIZED TRIAL

Italy

Therapeutic confirmatory (Phase III) EU CTIS Study details

BRCA-P: A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, International Phase 3 Study to Determine the Preventive Effect of Denosumab on Breast Cancer in Women Carrying a BRCA1 Germline Mutation

Spain, Germany, Austria

Therapeutic confirmatory (Phase III) EU CTIS Study details

"CUPCAKE": Early detection of triple negative breast cancer relapse: a clinical utility trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

"CUPCAKE": Early detection of triple negative breast cancer relapse: a clinical utility trial

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, Multicenter, Randomized, Double-Blind Study of Tobemstomig/RO7247669 Combined with Nab-Paclitaxel Compared with Pembrolizumab Combined with Nab-Paclitaxel in Participants with Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer

Czechia, Hungary, Poland, Spain, Germany, Denmark +2 more

Therapeutic exploratory (Phase II) EU CTIS Study details

Triple Negative Breast Cancer trials by city

Triple Negative Breast Cancer in Toronto Triple Negative Breast Cancer in Vancouver Triple Negative Breast Cancer in Montreal Triple Negative Breast Cancer in Calgary Triple Negative Breast Cancer in Edmonton Triple Negative Breast Cancer in Ottawa Triple Negative Breast Cancer in Winnipeg Triple Negative Breast Cancer in Quebec City Triple Negative Breast Cancer in Hamilton Triple Negative Breast Cancer in Kitchener Triple Negative Breast Cancer in London Triple Negative Breast Cancer in Halifax Triple Negative Breast Cancer in New York Triple Negative Breast Cancer in Los Angeles Triple Negative Breast Cancer in Chicago Triple Negative Breast Cancer in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease